# Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

> **NCT00697229** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 99 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B
- **BIOLOGICAL:** HBV-MPL vaccine

## Key facts

- **NCT ID:** NCT00697229
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1992-09
- **Primary completion:** 1996-05
- **Final completion:** 1998-12
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2008-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697229, "Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00697229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*